Business Wire

WA-T-MOBILE

Share
ICE Cobotics Simplifies Floor Cleaning with T IoT, From T-Mobile and Deutsche Telekom

Today, T-Mobile (NASDAQ: TMUS) announced that ICE Cobotics, a global leader in cleaning technologies and equipment, has chosen T IoT as its exclusive IoT connectivity solution worldwide to help their customers more easily manage fleets of floor cleaning robots.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005555/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Floor cleaning and technology company picks T IoT to power i-SYNERGY fleet management software and strengthen its global subscription service (Photo: Business Wire)

As part of the long-term agreement, T IoT — a comprehensive solution for global IoT connectivity, platform management and support — will deliver cellular connectivity to more than 7,500 new and existing ICE Cobotics intelligent and autonomous cleaning units across the world. This includes their newest product, Cobi 18, a compact autonomous floor scrubber which is designed to clean 5,000 to 7,000 square feet per hour, starting at less than $20 a day.

ICE Cobotics chose T IoT to simplify the delivery and execution of IoT solutions on a global scale, which bolsters their mission to streamline processes for its customers. Less than a year ago, the company launched an industry first: an all-inclusive subscription service for floor cleaning machines, parts and maintenance, and performance and monitoring software. The service provides customers with a more reliable, affordable, and cost predictive solution, allowing them to use their capital to expand their business versus having it tied up in equipment ownership.

T IoT supports ICE Cobotics’ subscription model by delivering cleaning performance data and insights to customers in the retail, grocery, convenience, healthcare, higher education, and hospitality industries. Imagine a major retail corporation that has hundreds of robots in service. The cellular connectivity allows a customer’s maintenance and facilities team to view their Clean Score — goal-based cleaning performance data generated by ICE Cobotics’ i-SYNERGY fleet management software. This takes the guess work out of tracking cleaning efficacy, developing efficiencies, and confirming each location is clean. Previously, they would have had to visit each store to inspect if cleaning happened, which takes time and money.

Additionally, T IoT reinforces ICE Cobotics’ commitment to eliminate downtime by delivering over the air software and firmware updates to its customers, as well as mechanical telemetry data, from sensors and cameras in each machine, back to the company. This gives them the ability to monitor and analyze critical information like hours of use, routes, temperature, and battery life — so they can determine if certain components of a machine are operating within tolerance, if service is required and if a part is near its end of life — to prevent problems before they happen.

“T IoT is critical to the success of our cleaning machines and our all-inclusive subscription service,” said Mike DeBoer, President, ICE Cobotics U.S. “The data we receive from our autonomous scrubbers allows us to deliver cleaning performance insights and an enhanced clean to our customers at an affordable price.”

“This is what T IoT was designed for — helping enterprises solve global IoT challenges and deliver innovative solutions that make their customers want more,” said Callie Field, President, T-Mobile Business Group. “Like ICE Cobotics, T-Mobile and Deutsche Telekom share a passion for the pursuit of simple and we salute their ongoing mission to make things easier for their customers.”

To learn more about ICE Cobotics, visit www.us.icecobotics.com.

For more information about T IoT, visit www.t-mobile.com/business/solutions/iot/t-iot-global.

Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.

About T-Mobile

T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile and Metro by T-Mobile. For more information please visit: https://www.t-mobile.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005555/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye